LO
Lou_Basenese
Community Contributor
Member since 2026
Views70Total number of views
Followers1Total number of followers
Comments0Total number of comments
Subscribers0Total number of subscribers
Veteran Wall Street analyst with 20+ years in equity research, co-founder of a 700K-subscriber financial publisher, former Morgan Stanley consultant, and regular contributor to FOX Business and CNBC.
No link added
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
70
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
LO
US$7.6
74.5% undervalued intrinsic discount
Fair Value
Profit Margin
18.91%
Future PE
25.12x
Price in 2031
US$10.68